Department of Nuclear Medicine, King Hussein Cancer Center, Queen Rania Al-Abdullah Street 202, P.O. Box 1269, Amman, Jordan.
Nuclear Medicine Clinic, Essen University Hospital, Hufelandstrasse 55, 45147, Essen, Germany.
BMC Med Imaging. 2021 Mar 17;21(1):49. doi: 10.1186/s12880-021-00580-w.
Staging of non-small-cell lung cancer (NSCLC) is a multidisciplinary process involving imaging, endoscopic and surgical techniques. This study aims at investigating the diagnostic accuracy of F-FDG PET/CT, CT scan, and endobronchial ultrasound/transbronchial needle aspirate (EBUS/TBNA) in preoperative mediastinal lymph nodes (MLNs) staging of NSCLC.
We identified all patients who were diagnosed with NSCLC at the King Hussein Cancer Center in Amman, Jordan, between July 2011 and December 2017. We collected their relevant clinical, radiological, and histopathological findings. The per-patient analysis was performed on all patients (N = 101) and then on those with histopathological confirmation (N = 57), followed by a per-lymph-node-station basis overall, and then according to distinct N-stage categories.
F-FDG PET/CT, in comparison to CT, had a better sensitivity (90.5% vs. 75%, p = 0.04) overall and in patients with histopathological confirmation (83.3% vs. 54.6%), and better specificity (60.5% vs. 43.6%, p = 0.01) overall and in patients with histopathological confirmation in MLN staging (60.6% vs. 38.2%). Negative predictive value of mediastinoscopy, EBUS/TBNA, and F-FDG PET/CT were (87.1%), (90.91%), and (83.33%) respectively. The overall accuracy was highest for mediastinoscopy (88.6%) and EBUS/TBNA (88.2%), followed by F-FDG PET/CT (70.2%). Dividing patients into N1 disease vs. those with N2/N3 disease yielded similar findings. Comparison between F-FDG PET/CT and EBUS/TBNA in patients with histopathological confirmation shows 28 correlated true positive and true negative findings with final N-staging. In four patients, F-FDG PET/CT detected metastatic MLNs that would have otherwise remained undiscovered by EBUS/TBNA alone. Lymph nodes with a maximal standardized uptake value (SUVmax) more than 3 were significantly more likely to be true-positive.
Multimodality staging of the MLNs in NSCLC is essential to provide accurate staging and the appropriate treatment. F-FDG PET/CT has better overall diagnostic utility when compared to the CT scan. The NPV of F-FDG PET/CT in MLNs is reliable and comparable to the NPV of EBUS/TBNA. SUVmax of MLNs can help in predicting metastases, but nevertheless, a positive F-FDG PET/CT MLNs particularly if such a result would change the treatment plan, should be verified histopathologically.
非小细胞肺癌(NSCLC)的分期是一个多学科的过程,涉及影像学、内镜和手术技术。本研究旨在探讨 18F-FDG PET/CT、CT 扫描和支气管内超声/经支气管针吸活检(EBUS/TBNA)在 NSCLC 术前纵隔淋巴结(MLN)分期中的诊断准确性。
我们在约旦安曼的侯赛因国王癌症中心确定了所有在 2011 年 7 月至 2017 年 12 月期间被诊断为 NSCLC 的患者。我们收集了他们的相关临床、放射学和组织病理学发现。对所有患者(N=101)和有组织病理学证实的患者(N=57)进行了逐例分析,然后对所有患者的淋巴结站进行了总体分析,然后根据不同的 N 期类别进行了分析。
与 CT 相比,18F-FDG PET/CT 总体上具有更好的敏感性(90.5% vs. 75%,p=0.04),在有组织病理学证实的患者中具有更好的敏感性(83.3% vs. 54.6%),总体上具有更好的特异性(60.5% vs. 43.6%,p=0.01),在有组织病理学证实的 MLN 分期患者中具有更好的特异性(60.6% vs. 38.2%)。纵隔镜、EBUS/TBNA 和 18F-FDG PET/CT 的阴性预测值分别为(87.1%)、(90.91%)和(83.33%)。纵隔镜(88.6%)和 EBUS/TBNA(88.2%)的总体准确性最高,其次是 18F-FDG PET/CT(70.2%)。将患者分为 N1 疾病与 N2/N3 疾病组,得出了类似的结果。在有组织病理学证实的患者中,18F-FDG PET/CT 与 EBUS/TBNA 的比较显示,28 个相关的真阳性和真阴性结果与最终的 N 分期一致。在 4 名患者中,18F-FDG PET/CT 检测到了纵隔淋巴结转移,如果仅进行 EBUS/TBNA,这些转移可能仍未被发现。最大标准化摄取值(SUVmax)大于 3 的淋巴结更有可能为真阳性。
多模态分期对 NSCLC 的 MLN 至关重要,可提供准确的分期和适当的治疗。与 CT 扫描相比,18F-FDG PET/CT 具有更好的总体诊断效用。18F-FDG PET/CT 在 MLN 中的阴性预测值是可靠的,与 EBUS/TBNA 的阴性预测值相当。MLN 的 SUVmax 有助于预测转移,但即便如此,阳性 18F-FDG PET/CT MLN 结果,如果这种结果会改变治疗计划,应通过组织病理学进行验证。